1.23

2.39% -0.0301

After Hours: 1.27 0.04 +3.25%

Virax Biolabs Group Ltd (VRAX)

Overview News Price History Discussions Forecast

Virax Biolabs Group Ltd stock is traded at $1.23, with a volume of 81,971. It is down -2.39% in the last 24 hours and down -29.71% over the past month. Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.

Previous Close:

$1.2601

Open:

$1.26

24h Volume:

81,971

Relative Volume:

0.23

Market Cap:

$5.34M

Revenue:

$79,300

Net Income/Loss:

$-6.92M

P/E Ratio:

-0.0648

EPS:

-18.9818

Net Cash Flow:

$-5.34M

1W Performance:

-16.42%

1M Performance:

-29.71%

6M Performance:

-51.38%

1Y Performance:

+51.76%

1-Day Range:

$1.22

$1.27

1-Week Range:

$1.22

$1.58

52-Week Range:

$0.60

$8.9999

Virax Biolabs Group Ltd Stock (VRAX) Company Profile

Name

Virax Biolabs Group Ltd

Sector

Healthcare (1167)

Industry

Biotechnology (670)

Phone

Address

Employee

Twitter

Next Earnings Date

Latest SEC Filings

VRAX's Discussions on Twitter

Compare VRAX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VRAX Virax Biolabs Group Ltd	1.23	5.34M	79,300	-6.92M	-5.34M	-18.98
VRTX Vertex Pharmaceuticals Inc	512.52	131.61B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	672.36	73.51B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	619.97	37.67B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	253.44	32.81B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	266.26	28.62B	3.81B	-644.79M	-669.77M	-6.24

Virax Biolabs Group Ltd Stock (VRAX) Latest News

Mar 18, 2025

Virax Biolabs Launches Clinical Study on T Cell Dysfunction - TipRanks

Mar 18, 2025

Virax Biolabs begins UK clinical study on T cell dysfunction - Investing.com India

Mar 18, 2025

Breakthrough T Cell Study: Virax Targets Long COVID and Chronic Fatigue Diagnosis Revolution - StockTitan

Mar 18, 2025

Mar 13, 2025

Virax Biolabs Highlights T-Cell Dysfunction in Post-Infection Syndromes - TipRanks

Mar 13, 2025

Virax Biolabs shares T-Cell dysfunction findings - Investing.com India

Mar 13, 2025

Virax Biolabs shares T-Cell dysfunction findings By Investing.com - Investing.com South Africa

Mar 13, 2025

Game-Changing Long COVID Diagnostic: Virax's New T-Cell Test Shows Promising Results - StockTitan

Mar 13, 2025

Mar 05, 2025

Virax Biolabs to Present at World Immune Regulation Meeting - TipRanks

Mar 05, 2025

Can Virax's T-Cell Research at WIRM 2025 Advance Post-Infection Syndrome Treatment? - StockTitan

Mar 05, 2025

Feb 28, 2025

Cosmos Health expands distribution of Avian Influenza kits - MSN

Feb 28, 2025

Short Interest in Virax Biolabs Group Limited (NASDAQ:VRAX) Expands By 205.8% - Defense World

Feb 28, 2025

Feb 25, 2025

Virax Biolabs aligns with US vaccine transparency efforts By Investing.com - Investing.com South Africa

Feb 25, 2025

Virax Biolabs Aligns with US Health Department on Vaccine Transparency - TipRanks

Feb 25, 2025

How Virax's Vaccine Testing Tech Could Capitalize on New Government Transparency Push - StockTitan

Feb 25, 2025

EXCLUSIVE: Virax Biolabs Says Its Tech Fits RFK Jr.'s HHS Goals On Vaccine Transparency - Benzinga

Feb 25, 2025

Feb 20, 2025

Contrasting Virax Biolabs Group (NASDAQ:VRAX) & Oruka Therapeutics (NASDAQ:ORKA) - Defense World

Feb 20, 2025

Feb 10, 2025

Market Watch: Virax Biolabs Group Ltd (VRAX)’s Noteworthy Drop, Closing at 1.71 - The Dwinnex

Feb 10, 2025

Feb 02, 2025

Virax Biolabs Group Limited (NASDAQ:VRAX) Short Interest Down 33.9% in January - Armenian Reporter

Feb 02, 2025

Jan 23, 2025

Cosmos Health Signs Expanded Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Saudi Arabia, the UAE, Qatar, and Kuwait - Yahoo Finance

Jan 23, 2025

Jan 14, 2025

Cosmos Health secures exclusive distribution agreement with Virax Biolabs - Yahoo Finance

Jan 14, 2025

Jan 13, 2025

Cosmos Health Secures Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Greece and Cyprus, with Additional Rights in Select European and GCC Countries - Lelezard

Jan 13, 2025

Jan 09, 2025